Cynthia Maria Alvares Brandão
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cynthia Maria Alvares Brandão has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Jose Gilberto Henriques Vieira
Universidade Federal de Sao Paulo, Brasil
7 shared publications - Marise Lazaretti-Castro
Departamento de Medicina, Divisão de Endocrinologia, Universidade Federal de São Paulo, São Paulo, SP, Brasil
4 shared publications - Lívia Marcela dos Santos
Department of Medicine, Endocrinology Unit, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
3 shared publications - Monique Nakayama Ohe
Department of Endocrinology Universidade Federal de São Paulo (UNIFESP) São Paulo Brazil
3 shared publications - Patricia Dreyer
Serviço de Densitometria Óssea Fleury Medicina e Saúde São Paulo SP Brasil
3 shared publications - Sthefanie Pallone
Department of Medicine, Endocrinology Unit, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil
3 shared publications
Latest Publications
- 26 June 2024
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (1) , 91-98
Vitamin D supplementation in primary hyperparathyroidism: effects on 1,25(OH)2 vitamin D and FGF23 levels
Purpose In patients with Primary Hyperparathyroidism (PHPT) vitamin D deficiency has been associated with more severe presentations. Our aim was to investigate the effects of Vitamin D supplementation on mineral homeostasis and related hormones in individuals with and without PHPT. Methods Individuals with and without PHPT (CTRL) received 14,000 IU/week of oral vitamin D3 for 12 weeks. At baseline and endpoint, blood samples were collected to measure 1,25(OH)2vitamin D (1,25(OH)2D), intact Fibroblast Growth Factor 23 (FGF23), 25OHD, Parathormone, and other biochemical markers. The 1,25(OH)2D measurement was performed using liquid chromatography and mass spectrometry (LC–MS/MS). Results 70 PHPT patients and 75 CTRL were included, and 55 PHPT and 64 CTRL completed the 12-week protocol. After the intervention, there were significant increases in the FGF23 levels (PHPT: 47.9 ± 27.1 to 76.3 ± 33.3; CTRL: 40.5 ± 13.9 to 59.8 ± 19.8 pg/mL, p < 0.001), and significant decreases in 1,25(OH)2D levels (PHPT: 94.8 ± 34.6 to 68.9 ± 25.3; CTRL: 68.7 ± 23.5 to 56.4 ± 20.7 pg/mL, p < 0.001). The reduction of 1,25(OH)2D was inversely associated with the increase of FGF23 in both the PHPT (r = −0.302, p = 0.028) and CTRL (r = −0.278, p = 0.027). No changes in plasmatic or uninary calcium concentrations were observed in both groups. Conclusion The weekly administration of 14,000 IU of Vitamin D3 was safe and efficient to increase in 25OHD levels in both groups. However, a paradoxical decrease in 1,25(OH)2D levels measured by LC–MS/MS was associated with a significant increase in FGF23 levels in both groups. This phenomenon might represent a defense against hypercalcemia after vitamin D supplementation and paves the way for new studies in this regard.
- 26 June 2024
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (1) , 91-98
Vitamin D supplementation in primary hyperparathyroidism: effects on 1,25(OH)2 vitamin D and FGF23 levels
Purpose In patients with Primary Hyperparathyroidism (PHPT) vitamin D deficiency has been associated with more severe presentations. Our aim was to investigate the effects of Vitamin D supplementation on mineral homeostasis and related hormones in individuals with and without PHPT. Methods Individuals with and without PHPT (CTRL) received 14,000 IU/week of oral vitamin D3 for 12 weeks. At baseline and endpoint, blood samples were collected to measure 1,25(OH)2vitamin D (1,25(OH)2D), intact Fibroblast Growth Factor 23 (FGF23), 25OHD, Parathormone, and other biochemical markers. The 1,25(OH)2D measurement was performed using liquid chromatography and mass spectrometry (LC–MS/MS). Results 70 PHPT patients and 75 CTRL were included, and 55 PHPT and 64 CTRL completed the 12-week protocol. After the intervention, there were significant increases in the FGF23 levels (PHPT: 47.9 ± 27.1 to 76.3 ± 33.3; CTRL: 40.5 ± 13.9 to 59.8 ± 19.8 pg/mL, p < 0.001), and significant decreases in 1,25(OH)2D levels (PHPT: 94.8 ± 34.6 to 68.9 ± 25.3; CTRL: 68.7 ± 23.5 to 56.4 ± 20.7 pg/mL, p < 0.001). The reduction of 1,25(OH)2D was inversely associated with the increase of FGF23 in both the PHPT (r = −0.302, p = 0.028) and CTRL (r = −0.278, p = 0.027). No changes in plasmatic or uninary calcium concentrations were observed in both groups. Conclusion The weekly administration of 14,000 IU of Vitamin D3 was safe and efficient to increase in 25OHD levels in both groups. However, a paradoxical decrease in 1,25(OH)2D levels measured by LC–MS/MS was associated with a significant increase in FGF23 levels in both groups. This phenomenon might represent a defense against hypercalcemia after vitamin D supplementation and paves the way for new studies in this regard.
- Open Access
- 7 March 2024
- Published by Elsevier in Jornal de Pediatria
- Vol. 100 (4) , 360-366
Alert for the high prevalence of vitamin D deficiency in adolescents in a large Brazilian sample
- 7 March 2024
- Published by Elsevier in Jornal de Pediatria
- Vol. 100 (4) , 360-366
Open AccessAlert for the high prevalence of vitamin D deficiency in adolescents in a large Brazilian sample
- Open Access
- 18 January 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (2) , 242-250
Concentrations of total, bioavailable, and free 25OHD in individuals with and without primary hyperparathyroidism and their correlations to DXA and trabecular bone score
Objective: This study aimed to investigate the association between 25OHD (total, bioavailable and free) with bone mass and microarchitecture among primary hyperparathyroidism (PHPT) patients and controls. Subjects and methods: Sixty-four patients in the preoperative period of PHPT and 63 matched controls, who had not taken vitamin D in the last three months. To calculate the bioavailable and free 25OHD, the genetic variants of the vitamin D-binding protein (DBP) were determined. Bone mineral density (BMD) was determined by dual-energy X-ray [...] ABSTRACT Objective: This study aimed to investigate the association between 25OHD (total, bioavailable and free) with bone mass and microarchitecture among primary hyperparathyroidism (PHPT) patients and controls. Subjects and methods: Sixty-four patients in the preoperative period of PHPT and 63 matched controls, who had not taken vitamin D in the last three months. To calculate the bioavailable and free 25OHD, the genetic variants of the vitamin D-binding protein (DBP) were determined. Bone mineral density (BMD) was determined by dual-energy X-ray
- 18 January 2023
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 67 (2) , 242-250
Open AccessConcentrations of total, bioavailable, and free 25OHD in individuals with and without primary hyperparathyroidism and their correlations to DXA and trabecular bone score
Objective: This study aimed to investigate the association between 25OHD (total, bioavailable and free) with bone mass and microarchitecture among primary hyperparathyroidism (PHPT) patients and controls. Subjects and methods: Sixty-four patients in the preoperative period of PHPT and 63 matched controls, who had not taken vitamin D in the last three months. To calculate the bioavailable and free 25OHD, the genetic variants of the vitamin D-binding protein (DBP) were determined. Bone mineral density (BMD) was determined by dual-energy X-ray [...] ABSTRACT Objective: This study aimed to investigate the association between 25OHD (total, bioavailable and free) with bone mass and microarchitecture among primary hyperparathyroidism (PHPT) patients and controls. Subjects and methods: Sixty-four patients in the preoperative period of PHPT and 63 matched controls, who had not taken vitamin D in the last three months. To calculate the bioavailable and free 25OHD, the genetic variants of the vitamin D-binding protein (DBP) were determined. Bone mineral density (BMD) was determined by dual-energy X-ray
- Open Access
- 16 November 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (5) , 694-706
Update on trabecular bone score
Trabecular bone score (TBS) is an indirect and noninvasive measure of bone quality. A low TBS indicates degraded bone microarchitecture, predicts osteoporotic fracture, and is partially independent of clinical risk factors and bone mineral density (BMD). There is substantial evidence supporting the use of TBS to assess vertebral, hip, and major osteoporotic fracture risk in postmenopausal women, as well as to assess hip and major osteoporotic fracture risk in men aged > 50 years. TBS complements BMD information and [...] ABSTRACT Trabecular bone score (TBS) is an indirect and noninvasive measure of bone quality. A low TBS indicates degraded bone microarchitecture, predicts osteoporotic fracture, and is partially independent of clinical risk factors and bone mineral density (BMD). There is substantial evidence supporting the use of TBS to assess vertebral, hip, and major osteoporotic fracture risk in postmenopausal women, as well as to assess hip and major osteoporotic fracture risk in men aged > 50 years. TBS complements BMD information and
- 16 November 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (5) , 694-706
Open AccessUpdate on trabecular bone score
Trabecular bone score (TBS) is an indirect and noninvasive measure of bone quality. A low TBS indicates degraded bone microarchitecture, predicts osteoporotic fracture, and is partially independent of clinical risk factors and bone mineral density (BMD). There is substantial evidence supporting the use of TBS to assess vertebral, hip, and major osteoporotic fracture risk in postmenopausal women, as well as to assess hip and major osteoporotic fracture risk in men aged > 50 years. TBS complements BMD information and [...] ABSTRACT Trabecular bone score (TBS) is an indirect and noninvasive measure of bone quality. A low TBS indicates degraded bone microarchitecture, predicts osteoporotic fracture, and is partially independent of clinical risk factors and bone mineral density (BMD). There is substantial evidence supporting the use of TBS to assess vertebral, hip, and major osteoporotic fracture risk in postmenopausal women, as well as to assess hip and major osteoporotic fracture risk in men aged > 50 years. TBS complements BMD information and
- 20 October 2022
- Published by Even3
Guia Prático em Osteometabolismo
A relevância e a abordagem consistente dos temas reunidos no Guia Prático em Osteometabolismo asseguraram a publicação dessa nova edição. Preparada pelos membros do Departamento de Metabolismo Ósseo e Mineral da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) e por seus colaboradores, oferece uma visão ainda mais detalhada sobre condições enfrentadas diariamente por clínicos e especialistas, como diabetes mellitus, osteoporose, hipertireoidismo e hipoparatireoidismo. Com isso, o guia mantém a sua condição como material de consulta e referência para profissionais da Endocrinologia e áreas relacionadas.
- 20 October 2022
- Published by Even3
Guia Prático em Osteometabolismo
A relevância e a abordagem consistente dos temas reunidos no Guia Prático em Osteometabolismo asseguraram a publicação dessa nova edição. Preparada pelos membros do Departamento de Metabolismo Ósseo e Mineral da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) e por seus colaboradores, oferece uma visão ainda mais detalhada sobre condições enfrentadas diariamente por clínicos e especialistas, como diabetes mellitus, osteoporose, hipertireoidismo e hipoparatireoidismo. Com isso, o guia mantém a sua condição como material de consulta e referência para profissionais da Endocrinologia e áreas relacionadas.
- 2 February 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (9) , E331-E333
Dermatoporosis and osteoporosis: cross‐sectional pilot study
- 2 February 2022
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (9) , E331-E333
Dermatoporosis and osteoporosis: cross‐sectional pilot study
- Open Access
- 29 March 2021
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 65 (AHEAD) , 381-385
No association between vitamin D status and COVID-19 infection in São Paulo, Brazil
In recent years the immunomodulatory actions of vitamin D, a steroid hormone, have been extensively studied. In 2020, due to the COVID-19 pandemic, the question arose as to 25(OH)D status would be related to susceptibility to SARS-CoV-2 infection, since several studies pointed out a higher prevalence and severity of the disease in populations with low levels of 25(OH)D. Thus, we investigated the 25(OH)D levels in adults "Detected" positive for SARS CoV-2 by RT-PCR (reverse transcriptase polymerase chain reaction) test, and in negative controls, "not Detected", using the Fleury Group's examination database, in Sao Paulo, Brazil. Of a total of 14.692 people with recent assessments of 25(OH)D and RT-PCR tests for COVID-19, 2.345 were positive and 11.585 were negative for the infection. The groups did not differ in the percentage of men and women, or in the age distribution. There were no differences in the distribution of 25(OH)D between the two groups (p = 0.08); mean 25(OH)D of 28.8 +/- 21.4 ng/mL and 29.6 +/- 18.1 ng/mL, respectively. In the specific population studied, clinical, environmental, socioeconomic and cultural factors should have greater relevance than 25(OH)D in determining the susceptibility to COVID-19.
- 29 March 2021
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 65 (AHEAD) , 381-385
Open AccessNo association between vitamin D status and COVID-19 infection in São Paulo, Brazil
In recent years the immunomodulatory actions of vitamin D, a steroid hormone, have been extensively studied. In 2020, due to the COVID-19 pandemic, the question arose as to 25(OH)D status would be related to susceptibility to SARS-CoV-2 infection, since several studies pointed out a higher prevalence and severity of the disease in populations with low levels of 25(OH)D. Thus, we investigated the 25(OH)D levels in adults "Detected" positive for SARS CoV-2 by RT-PCR (reverse transcriptase polymerase chain reaction) test, and in negative controls, "not Detected", using the Fleury Group's examination database, in Sao Paulo, Brazil. Of a total of 14.692 people with recent assessments of 25(OH)D and RT-PCR tests for COVID-19, 2.345 were positive and 11.585 were negative for the infection. The groups did not differ in the percentage of men and women, or in the age distribution. There were no differences in the distribution of 25(OH)D between the two groups (p = 0.08); mean 25(OH)D of 28.8 +/- 21.4 ng/mL and 29.6 +/- 18.1 ng/mL, respectively. In the specific population studied, clinical, environmental, socioeconomic and cultural factors should have greater relevance than 25(OH)D in determining the susceptibility to COVID-19.
- Open Access
- 22 January 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (4) , e1920-e1921
Letter to the Editor from Dreyer, et al: “Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF”
- 22 January 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 106 (4) , e1920-e1921
Open AccessLetter to the Editor from Dreyer, et al: “Osteoporosis in Premenopausal Women: A Clinical Narrative Review by the ECTS and the IOF”
- Open Access
- 1 December 1999
- Published by FapUNIFESP (SciELO) in Archives of Endocrinology and Metabolism
- Vol. 43 (6) , 401-408
Fatores envolvidos no pico de massa óssea
A massa óssea de um indivíduo adulto, que está estreitamente relacionada ao risco de fraturas osteoporóticas, depende da diferença entre o pico de massa óssea alcançado no final do período de maturação sexual e esquelética, e as perdas acumuladas durante a vida. A enorme variabilidade observada no pico de massa óssea da adolescência está relacionada, principalmente, a fatores genéticos, mas também a parâmetros antropométricos, como peso e altura, hábitos dietéticas, influências hormonais diversas, atividade física, uso de medicamentos e doenças intercorrentes. A identificação dos fatores envolvidos na aquisição do pico de massa óssea na infância e adolescência e a compreensão deste longo período de maturação esquelética, permitirão a criação de estratégias para prevenção da osteoporose.
- 1 December 1999
- Published by FapUNIFESP (SciELO) in Archives of Endocrinology and Metabolism
- Vol. 43 (6) , 401-408
Open AccessFatores envolvidos no pico de massa óssea
A massa óssea de um indivíduo adulto, que está estreitamente relacionada ao risco de fraturas osteoporóticas, depende da diferença entre o pico de massa óssea alcançado no final do período de maturação sexual e esquelética, e as perdas acumuladas durante a vida. A enorme variabilidade observada no pico de massa óssea da adolescência está relacionada, principalmente, a fatores genéticos, mas também a parâmetros antropométricos, como peso e altura, hábitos dietéticas, influências hormonais diversas, atividade física, uso de medicamentos e doenças intercorrentes. A identificação dos fatores envolvidos na aquisição do pico de massa óssea na infância e adolescência e a compreensão deste longo período de maturação esquelética, permitirão a criação de estratégias para prevenção da osteoporose.